Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 343

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors

Open access
Vivanco, Igor, Robins, H. Ian, Rohle, Daniel, Campos, Carl, Grommes, Christian, Nghiemphu, Phioanh Leia, Kubek, Sara, Oldrini, Barbara, Chheda, Milan G., Yannuzzi, Nicolas, Tao, Hui, Zhu, Shaojun, Iwanami, Akio, Kuga, Daisuke, Dang, Julie, Pedraza, Alicia, Brennan, Cameron W., Heguy, Adriana, Liau, Linda M., Lieberman, Frank, Yung, W. K. Alfred, Gilbert, Mark R., Reardon, David A., Drappatz, Jan, Wen, Patrick Y., Lamborn, Kathleen R., Chang, Susan M., Prados, Michael D., Fine, Howard A., Horvath, Steve, Wu, Nian, Lassman, Andrew B., DeAngelis, Lisa M., Yong, William H., Kuhn, John G., Mischel, Paul S., Mehta, Minesh P., Cloughesy, Timothy F., Mellinghoff, Ingo K.·2012·Cancer Discovery

Abstract

Activation of the epidermal growth factor receptor (EGFR) in glioblastoma (GBM) occurs through mutations or deletions in the extracellular (EC) domain. Unlike lung cancers with EGFR kinase domain (KD) mutations, GBMs respond poorly to the EGFR inhibitor erlotinib. Using RNAi, we show that GBM cells carrying EGFR EC mutations display EGFR addiction. In contrast to KD mutants found in lung cancer, glioma-specific EGFR EC mutants are poorly inhibited by EGFR inhibitors that target the active kinase conformation (e.g., erlotinib). Inhibitors that bind to the inactive EGFR conformation, however, potently inhibit EGFR EC mutants and induce cell death in EGFR-mutant GBM cells. Our results provide first evidence for single kinase addiction in GBM and suggest that the disappointing clinical activity of first-generation EGFR inhibitors in GBM versus lung cancer may be attributed to the different conformational requirements of mutant EGFR in these 2 cancer types. Significance: Approximately 40% of human glioblastomas harbor oncogenic EGFR alterations, but attempts to therapeutically target EGFR with first-generation EGFR kinase inhibitors have failed. Here, we demonstrate selective sensitivity of glioma-specific EGFR mutants to ATP-site competitive EGFR kinase inhibitors that target the inactive conformation of the catalytic domain. Cancer Discov; 2(5); 458–71. ©2012 AACR. Read the Commentary on this article by Park and Lemmon, p. 398. This article is highlighted in the In This Issue feature, p. 377.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-11-0284

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

See all 343

Metadata

Authors
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., Tao, H., Zhu, S., Iwanami, A., Kuga, D., Dang, J., Pedraza, A., Brennan, C. W., Heguy, A., Liau, L. M., Lieberman, F., Yung, W. K. A., Gilbert, M. R., Reardon, D. A., Drappatz, J., Wen, P. Y., Lamborn, K. R., Chang, S. M., Prados, M. D., Fine, H. A., Horvath, S., Wu, N., Lassman, A. B., DeAngelis, L. M., Yong, W. H., Kuhn, J. G., Mischel, P. S., Mehta, M. P., Cloughesy, T. F., & Mellinghoff, I. K.
Venue
Cancer Discovery
Published
2012-05-01
Volume
2
Issue
5
Pages
458-471
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W1963558982
Cited by
343
References
11
FWCI
13.32
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors. https://app.cochat.ai/papers/10.1158/2159-8290.cd-11-0284
The paper
Vivanco, I., Robins, H. I., Rohle, D., Campos, C., Grommes, C., Nghiemphu, P. L., Kubek, S., Oldrini, B., Chheda, M. G., Yannuzzi, N., Tao, H., Zhu, S., Iwanami, A., Kuga, D., Dang, J., Pedraza, A., Brennan, C. W., Heguy, A., Liau, L. M., . . . Mellinghoff, I. K. (2012). Differential Sensitivity of Glioma- versus Lung Cancer–Specific EGFR Mutations to EGFR Kinase Inhibitors. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-11-0284

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.